Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab and Radiotherapy in Inoperable Stage III NSCLC
NCT00115518Phase 2Completed
- Sponsor
- Heidelberg University
- Start
- May 2005
- Primary completion
- Jun 2009
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of cetuximab in non-small cell lung cancer (NSCLC), sponsored by Heidelberg University. Primary endpoint: Safety and Feasibility at 3 years. Started May 2005; status: completed.
02
Drugs
cetuximab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00115518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00115518.